In this article, we will discuss Ramucirumab (19). So, let’s get started.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
RPLS has been reported with a rate of <0.1% in clinical studies with Ramucirumab. Confirm the diagnosis of RPLS with MRI and discontinue Ramucirumab in patients who develop RPLS. Symptoms may resolve or improve within days, although some patients with RPLS can experience ongoing neurologic sequelae or death.